MicroRNA-145通过丝裂原活化蛋白激酶和磷脂酰肌醇3激酶/蛋白质丝氨酸苏氨酸激酶通路调控肺癌A549细胞系转移及侵袭

doi:10.16098/j.issn.0529-1356.2018.05.011

摘要/Abstract

摘要：

目的探讨microRNA-145(miR-145)对非小细胞肺癌A549细胞转移、侵袭及对丝裂原活化蛋白激酶(MAPK)和磷脂酰肌醇3激酶/蛋白质丝氨酸苏氨酸激酶（PI3K/AKT）通路的作用。方法将非小细胞肺癌A549细胞分成miR-145模拟物（mimics）组和negative-mimics组（miR-NC）以及antago miR-145组（抑制剂组）和antago miR control 组（antago-NC），采用Transwell迁移实验及基质胶侵袭实验等检测miR-145对人非小细胞肺癌A549迁移、侵袭能力的影响；Western blotting方法分析miR-145对MAPK和PI3K/AKT通路的影响。此外，采用细胞外调节蛋白激酶（ERK）及AKT的通路抑制剂分别作用于A549细胞系，检测A549细胞迁移、侵袭能力的改变。结果 miR-145 mimics组穿过细胞数（90.67±10.33）明显少于miR-NC组（175.33±23.67），miR-145 mimics组穿过基质胶的细胞数（153.33±22.33）少于miR-NC组 (77.33±13.67），P<0.05；antago-NC组通过小室的细胞数量以及穿过基质胶的细胞数量明显少于antago miR-145组（P<0.05），结果说明，miR-145具有抑制非小细胞肺癌A549细胞迁移、侵袭的能力；miR-145 mimics转染可分别抑制A549细胞中90%、78%以及73%的ERK1/2、AKT的ser-473位点和thr-308位点的磷酸化，antago miR-145转染可促进A549细胞中ERK1/2、AKT的ser-473位点和thr-308位点的磷酸化，增加115%、125%以及129%，而当抑制MAPK通路及PI3K/AKT通路的激活后，A549细胞的转移及侵袭能力下降。结论 miR-145通过MAPK和PI3K/AKT通路调控肺癌A549细胞转移及侵袭。

关键词: 非小细胞肺癌, A549, miR-145, 转移, 侵袭, 实时定量聚合酶链反应, 免疫印迹法

Abstract:

Objective To study the effect of microRNA-145(miR-145) on the migration and invasion and on the mitogen-activated protein kinase(MAPK) and phosphatiolylinositol 3 kinase/protein serine threonine kinase(PI3K/AKT) pathways in non-small cell lung cancer A549 cells. Methods The A549 cells were divided into miR-145 mimics, negative mimics (miR-NC), antago miR-145 and antago-miR control (antago-NC) groups. Transwell migration experiment and matrix matrigel invasion experiment were used to detect the influence of miR-145 on the migration and invasion ability of human non-small cell lung cancer A549. Western blotting method analyzed the effect of miR-145 on MAPK and PI3K/AKT pathways. In addition, the inhibitors of extracellular regulated protein kinase(ERK) and AKT pathways were used to detect the changes of the cell migration and invasion in A549 cell lines. Results The amount of miR-145 mimics group through transwell chambers was significantly less than the miR-NC group (175.33±23.67). The miR-145 mimics group had a lower number of cells through matrigel matrix than miR-NC group (153.33±22.33), P<0.05. When the expression of miR-145 was inhibited, the number of cells in antago-NC group through Transwell chambers or matrigel matrix were significantly less than the antago miR-145 group (245.00±23.00) and (185.00±12.00), P<0.05. The above results proved that miR-145 inhibited cell migration and invasion ability of A549 cells. The transfection of miR-145 mimics respectively inhibited the phosphorylation of ERK1/2, AKT (ser-473) and AKT (thr-308) about 90%, 78% and 73%, while the transfection of antago miR-145 promoted the phosphorylation of ERK1/2, AKT (ser-473) and AKT (thr-308) and rose up to 115%, 125%and 129%. The migration and invasion ability of A549 cells decreased when the activation of MAPK pathway and PI3K/AKT pathways were inhibited. Conclusion miR-145 regulates lung cancer A549 cell migration and invasion through MAPK and PI3K/AKT pathways, which may provide reliable research results for the treatment of lung cancer.

Key words: Lung cancer, A549, miR-145, Migration, Invasion, Real-time PCR, Western blotting

夏迎晨甄杰叶飞郭惠明张丽娟. MicroRNA-145通过丝裂原活化蛋白激酶和磷脂酰肌醇3激酶/蛋白质丝氨酸苏氨酸激酶通路调控肺癌A549细胞系转移及侵袭[J]. 解剖学报, 2018, 49(5): 630-635.

Effects of microRNA-145 on the migration and invasion of lung cancer cell line A549 through mitogen-activated protein kinase and phosphatidylinositol 3 kinase/protein-serine-threonine kinase pathways. Effects of microRNA-145 on the migration and invasion of lung cancer cell line A549 through mitogen-activated protein kinase and phosphatidylinositol 3 kinase/protein-serine-threonine kinase pathways[J]. Acta Anatomica Sinica, 2018, 49(5): 630-635.

参考文献

［1］ Arrieta O, Anaya P, Morales-Oyarvide Ⅴ,et al.Cost-effectiveness analysis of EGFR mutation testing in patients with non-small cell lung cancer (NSCLC) with gefitinib or carboplatin-paclitaxel［J］. Eur J Health Econ,2016,17(7):855-863.

［2］ Mirshahidi HR, Hsueh CT. Updates in non-small cell lung cancer-insights from the 2009 45th annual meeting of the American Societyof Clinical Oncology［J］. J Hematol Oncol,2010,3(1):18.

［3］ Monteiro J, Fodde R. Cancer stemness and metastasis: therapeutic consequences and perspectives［J］. Eur J Cancer, 2010,46(7)):1198-1203.

［4］ Fazi F, Fontemaggi G. MicroRNAs and lymph node metastatic disease in lung cancer［J］. Thorac Surg Clin,2012,22(2): 167-175.

［5］ Inamura K, Ishikawa Y. Lung cancer progression and metastasis from the prognostic point of view［J］. Clin Exp Metastasis,2010,27(6):389-397

［6］ Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14［J］.Cell,1993,75(5):843-854.

［7］ Bartels CL, Tsongalis GJ. MicroRNAs: Novel biomarkers for human cancer［J］.Ann Biol Clin,2010,68(3):263-272.

［8］ Liu X, Sempere LF, Ouyang H, et al. MicroRNA-31 functions as an oncogenic microRNA in mouse and human lung cancer cells by repressing specific tumor suppressors［J］. J Clin Invest, 2010, 120(4):1298-1309.

［9］ Puiss égur MP, Mazure NM, Bertero T, et al. miR-210 is overexpressed in late stages of lung cancer and mediates mitochondrial alterations associated with modulation of HIF-1 activity［J］. Cell Death Differ,2011, 18(3):465-478.

［10］Li Y, Li Y, Liu J, et al. Expression levels of microRNA-145 and microRNA-10b are associated with metastasis in non-small cell lung cancer［J］.Cancer Biol Ther,2016,17(3): 272-279.

［11］Chen Z, Zeng HZ, Guo Y, et al. miRNA-145 inhibits non-small cell lung cancer cell proliferation by targeting c-Myc ［J］. J Exp Clin Cancer Res,2010,29(1): 151.

［12］Zhang Y, Lin Q. MicroRNA-145 inhibits migration and invasion by down-regulating FSCN1 in lung cancer［J］. Int J Clin Exp Med,2015,8(6): 8794-8802.

［13］Wang Y, Sun YM. The impact of microRNA143 and microRNA145 on the growth cycle and apoptosis of the QBC939 in bile duct cancer cells ［J］. Journal of Nanjing Medical University (Natural Science Edition), 2010, 30(5): 612-616. (in Chinese)

王勇，孙跃明. microRNA143、microRNA145对胆管癌细胞株QBC939 生长周期及凋亡的影响［J］. 南京医科大学学报(自然科学版),2010, 30(5): 612-616.

［14］Zhang J,Han C,Wu T. Microrna-26A enhances cholangiocarcinoma growth through degradation of GSK-3β and activation of β-catenin［J］. Hepatology,2011, 54(Suppl 1):1356A-1357A.

［15］Yan X, Chen X, Liang H, et al. miR-143 and miR-145 synergistically regulate ERBB3 to suppress cell proliferation and invasion in breast cancer ［J］. Mol Cancer,2014,13(1),220.［16］Gregersen LH, Jacobsen AB, Frankel LB, et al. MicroRNA-145 targets YES and STAT1 in colon cancer cells ［J］. PLoS One,2010, 5 (1):e8836.

［17］Cho WC, Chow AS, Au JS. MiR-145 inhibits cell proliferation of human lung adenocarcinoms by targeting EGFR and NUDT1［J］. RNA Bio,2011, 8 (1):125-131.

［18］Fang F, Chen CX, Ma CL. Expression and clinical significance of miRNA-145 in different cervical tissues of xinjiang uygur and han women ［J］. Chinese Clinical Study, 2016,29(2):173-177. (in Chinese)

方芳，陈彩霞，马彩玲. 新疆维吾尔族和汉族妇女不同宫颈组织中miRNA-145的表达及临床意义［J］. 中国临床研究,2016,29(2):173-177.

［19］Xing XF，Li ZY. The expression and function of miR-143 and miR-145 in gastric cancer ［J］. Journal of Gastroenterology, 2015, 18(1): 50-53.(in Chinese)

邢晓芳，李子禹. miR-143和miR-145在胃癌中的表达及功能研究［J］. 中华胃肠外科杂志,2015, 18(1): 50-53.

［20］Guo YH, Jiang B, Shi J, et al. EGFR-AKT signaling pathway reduced expression of miRNA-145 in lung cancer cells ［J］. Modern Oncology Medicine, 2013, 21(12):2652-2655. (in Chinese)

郭跃辉，姜斌，时娟，等. EGFR-AKT信号通路下调肺癌细胞miRNA-145的表达［J］. 现代肿瘤医学,2013, 21(12):2652-2655.

［21］Guo W, Ren D, Chen X, et al. HEF1 promotes epithelial mesenchymal transition and bone invasion in prostate cancer under the regulation of microRNA-145 ［J］. J Cell Biochem,2013, 114(7):1606-1615.

［22］Zhao YJ,Chun H,Li XL,et la.Effects of crocin on the cell proliferation and extracellular regulated protein kinases pathway in human umbilical vein endothelial cells［J］.Acta Anatomica Sinica,2017,48(3):282-286. (in Chinese)

赵玉娇,春花,李鑫磊,等. 藏红花素对人脐静脉内皮细胞增殖及细胞外调节蛋白激酶信号通路的影响［J］. 解剖学报,2017,48(3):282-286.

［23］Boufraqech M, Zhang L, Jain M, et al. miR-145 suppresses thyroid cancer growth and metastasis and targets AKT3 ［J］. Endocr Relat Cancer, 2014, 21(4): 517-531.

［24］Guo YH, Zhang C, Shi J, et al. Abnormal activation of the EGFR signaling pathway mediates the downregulation of miR-145 through the ERK1/2 in non-small cell lung cancer ［J］. Oncol Rep, 2014, 31(4): 1940-1946.

[1]	洪晓敏李三强崔钦奕郑润月杨孟利罗仁利李前辉 . 酒精性肝纤维化核因子κB信号通路与性别的差异 [J]. 解剖学报, 2024, 55(1): 55-61.
[2]	谢惠兰方芳林毅. Chir99021调控Wnt/β-catenin 信号通路抑制大鼠牙髓干细胞成骨诱导分化的机制[J]. 解剖学报, 2024, 55(1): 67-72.
[3]	魏茜茜李超红赵晨露唐家萍刘玉珍. 大鼠颈上神经节中Ⅰ组代谢型谷氨酸受体表达及慢性间歇性低氧对其的影响 [J]. 解剖学报, 2024, 55(1): 3-9.
[4]	袁蕾杨智伟杨惠刘政海何洁万炜. 三七总皂苷抑制小鼠星形胶质细胞活化缓解完全弗氏佐剂所致炎性痛 [J]. 解剖学报, 2024, 55(1): 25-31.
[5]	马婷婷陈建红刘爱翠李海宁. 抑制lncRNA TUG1下调核苷酸结合寡聚结构域样受体蛋白1炎症小体在延缓阿尔茨海默病进展的作用 [J]. 解剖学报, 2024, 55(1): 32-42.
[6]	邹成功冯浩陈兵唐辉邵川孙谋杨荣何家全. 创伤性颅脑损伤中神经功能障碍与认知功能损伤的动态变化 [J]. 解剖学报, 2024, 55(1): 43-48.
[7]	吕海燕沈西雅赵富生朱梅. 松茸多糖对 1-甲基-4-苯基-吡啶离子诱导 PC12 细胞损伤的影响 [J]. 解剖学报, 2024, 55(1): 49-54.
[8]	郑丽平刘霞杜晓华吴亚娟刘珊珊 . 脑源性神经营养因子在牦牛与黄牛端脑不同区域的表达与分布 [J]. 解剖学报, 2024, 55(1): 10-16.
[9]	郝永明郭磊周程辉裴汉军李莉赵哲 . 改良腹主动脉缩窄法建立心肌肥厚模型[J]. 解剖学报, 2024, 55(1): 120-124.
[10]	许亚平余悦欣陈金福王柯柯郭志坤 . 高龄大鼠心室肌间质弹性纤维和胶原纤维的结构分布特征及其机制 [J]. 解剖学报, 2023, 54(6): 716-721.
[11]	王文娟丁雨桐苏昊任捷孙艳荣王涵菲陆嘉莉张林倩白钰秦丽华. 低雌激素状态下大鼠海马及纹状体Nogo-A的表达变化[J]. 解剖学报, 2023, 54(6): 620-627.
[12]	张琴杨俊霞蒋青松. 福辛普利对糖尿病视网膜病变小鼠血管紧张素转化酶2和血管内皮生长因子的影响[J]. 解剖学报, 2023, 54(6): 628-634.
[13]	梁盼盼禹爱梅杜静寇文辉王欢欢宋爱霞. 基于c-Jun氨基末端激酶/p38丝裂原活化蛋白激酶信号通路探讨阿魏酸钠对偏头痛大鼠炎症反应的抑制作用[J]. 解剖学报, 2023, 54(6): 652-659.
[14]	徐颖刘斌郑兴何宗钊. 补体C3a受体在盲肠结扎穿孔致脓毒症大鼠认知障碍中的作用及机制 [J]. 解剖学报, 2023, 54(6): 668-675.
[15]	刘哲川李坤马帅男孟家琪王艳芹. 利拉鲁肽对百草枯诱导的小鼠帕金森病模型炎症及线粒体融合/分裂的影响 [J]. 解剖学报, 2023, 54(6): 676-681.